Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE and National Cancer Institute team up for nanoparticle imaging agents

This article was originally published in Clinica

Executive Summary

GE Healthcare has signed a two-year agreement with the US National Cancer Institute to develop nanoparticle-based imaging agents for the diagnosis and treatment of cancer and heart disease. The institute's Nanotechnology Characterization Laboratory will evaluate the safety and feasibility of GE's nanoparticle diagnostic imaging agents. The Chalfont St Giles, UK firm hopes they could lead to earlier detection of cancers and cardiac diseases, and monitor the effectiveness of treatments, by allowing doctors to see and target disease with higher resolution and sensitivity.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel